U.S. Fibromyalgia Patients Currently Taking an Approved Therapy are More Likely to Request a Discontinuation of Their Trea

EXTON, Penn.--(BUSINESS WIRE)-- Data from a recent report from BioTrends Research Group suggest that U.S. fibromyalgia patients who are currently taking one of the three agents approved for the treatment of fibromyalgia – Eli Lilly’s Cymbalta, Pfizer’s Lyrica, and Forest Laboratories/Cypress Biosciences’ Savella – may have higher expectations for their treatment than patients taking off-label therapies. Approximately 40% of surveyed patients taking an approved therapy indicate they are “very unlikely” to ask their doctor to switch their therapy in the next year, compared with more than half of surveyed patients taking an off-label treatment.

“These data suggest that patients currently taking an approved therapy are not well-established on their current treatments, creating a higher risk of drug switching in these patients” said CNS analyst Andrea Buurma. “This indicates there is a significant opportunity for emerging novel agents.”

Surveyed patients express they are most likely to request a switch to an agent that offers improvement over their current therapy in treating pain, fatigue, and/or sleep problems. “More than two-thirds of patients indicated they would be somewhat or very likely to switch to an emerging agent that offers improvement in these areas” Ms. Buurma said.

PatientTrends™: Fibromyalgia is a yearly report that investigates patients’ attitudes, perceptions and behavior regarding their disease, with a focus on the patient’s path to diagnosis and their perception of their interaction with their physician. The report looks at what drives patients’ satisfaction with their current fibromyalgia treatment and identifies which drug attributes are most likely to prompt a patient to request a switch to an emerging treatment. This report is based on a survey fielded in January and February of 2011 with 500 U.S. patients diagnosed with fibromyalgia.

About BioTrends Research Group, LLC

BioTrends Research Group, LLC (www.bio-trends.com) provides syndicated market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends’ publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com. BioTrends Research Group, LLC is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

BioTrends Research Group, LLC
Sharon Funk, 404-223-2963
[email protected]
or
Decision Resources, Inc.
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:   Health  Biotechnology  Genetics  Medical Devices  Pharmaceutical  Other Health  Research  Science  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.